구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab) RemeGen·HER2 91 trials |
|---|---|
Overview Program | Disitamab Vedotin(RC48) Plus Tratuzumab |
Overview Company | RemeGen |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linker |
MoA Mechanism | ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis |
MoA Biomarker | PD-1 blockade and gemcitabine/cisplatin in high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | interstitial lung disease), with corresponding management strategies |
Clinical Safety signal | interstitial lung disease), with corresponding management strategies |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab) RemeGen·HER2 91 trials |
|---|---|
Overview Program | Disitamab Vedotin(RC48) Plus Tratuzumab |
Overview Company | RemeGen |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linker |
MoA Mechanism | ADC is revealed to exert its antitumor effect by inducing G2/M arrest and caspase-dependent apoptosis |
MoA Biomarker | PD-1 blockade and gemcitabine/cisplatin in high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | interstitial lung disease), with corresponding management strategies |
Clinical Safety signal | interstitial lung disease), with corresponding management strategies |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교